Sugammadex: A new concept for antagonizing muscle relaxants;Sugammadex: Eine neue ära in der antagonisierung von muskelrelaxanzien

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 44, Issue 5, 2009, Pages 368-374

  Rex, Christopher ^a   Pühringer, Friedrich K ^a  

^a Klinikum am Steinenberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYCLODEXTRIN; ATRACURIUM; BETA CYCLODEXTRIN; GAMMA CYCLODEXTRIN; MIVACURIUM; MUSCLE RELAXANT AGENT; NEOSTIGMINE; PANCURONIUM; PYRIDOSTIGMINE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM; ANDROSTANE DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

DRUG ANTAGONISM; DRUG BINDING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; KIDNEY CLEARANCE; NEUROMUSCULAR BLOCKING; REVIEW; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; KIDNEY; MUSCLE RELAXATION; PHYSIOLOGY;

EID: 67651208172     PISSN: 09392661     EISSN: 14391074     Source Type: Journal    
DOI: 10.1055/s-0029-1224784     Document Type: Review

References (16)

1. Adam JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-1816 (Pubitemid 34415376)
2. Bom A, Bradley M, Cameron K et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem 2002; 41: 265-270 (Pubitemid 34126377)
3. Bom AH, Egmond J van, Hope F, Pol F van de. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion. Anesthesiology 2003; 99: A1158
4. Bom A, Epemolu O, Hope F, Rutherford S, Thomson K. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007; 7(3): 298-302 (Pubitemid 46731191)
5. Cammu G, de Kam PJ, Demeyer I, Decoopman M, Peeters PA, Smeets JM, Foubert L. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100(3): 373-379 (Pubitemid 351773650)
6. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96: 473-479 (Pubitemid 43174660)
7. de Boer HD, van Egmond J, van de Pol F, Bom A, Driessen JJ, Booij LHDJ. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 2006; 97: 681-686 (Pubitemid 44593864)
8. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: A multicenter, dose-fi nding and safety study. Anesthesiology 2007; 107(2): 239-245 (Pubitemid 47196486)
9. Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104: 582-584 (Pubitemid 46309876)
10. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99: 632-637 (Pubitemid 37051978)
11. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008; 100: 622-630 (Pubitemid 351774353)
12. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703 (Pubitemid 41415517)
13. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-fi nding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 555-562 (Pubitemid 46309872)
14. Kam dePJ, Kuijk van J, Smeets J, Thomsen T, Peeters P . Single iv use sugammadex up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007; 105: A1580
15. Naguib M. Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575-581 (Pubitemid 46331731)
16. Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy 2007; 27(8): 1181-1188 (Pubitemid 47173661)